Allogenica Secures €2.5 Million Grant to Advance Universal CAR-T Therapy and Strengthen France’s Biotherapy Leadership
Summary
Allogenica received a 2.5 million grant from the French governments France 2030 program to support the industrialization of its breakthrough universal CAR-T therapies for blood cancers. This initiative will stimulate economic and industrial growth, including a fourfold increase in Allogenicas R&D and workforce by 2026, greater competitiveness for France in CAR-T production compared to the US and China, and the establishment of a CAR-T biomanufacturing facility in France by 2028.The company is also focused on sustainable biomanufacturing practices, prioritizing eco-design, waste reduction and energy-efficient processes to minimize its environmental impact while advancing medical innovation.With its innovative technology, strong industry partnerships and strategic funding, Allogenica is poised to redefine the future of CAR-T therapies, making cutting-edge cancer treatment more accessible, affordable and scalable than ever before.Allogenica is a preclinical-stage biotechnology company developing therapeutic programs on a breakthrough cell therapy platform focused on cancer, rare diseases, and autoimmune disorders. Translates a double ambition: to transform key sectors of our economy (energy, automotive, health, aeronautics, space) through technological and industrial innovation, and to position France not only as a participant but as a leader in the world of tomorrow. The goal: to allow them to respond competitively to environmental challenges and attractiveness of the world to come, and to emerge as future champions in our fields of excellence, thus strengthening French sovereignty and independence in key sectors. Will be implemented collectively: the plan is thought out and deployed in consultation with economic, academic, local, and European actors who have contributed to determining strategic orientations and flagship actions.